CytRx Corporation (CYTR) Shares are Down -6.86%

CytRx Corporation (CYTR) : During the past 4 weeks, traders have been relatively bearish on CytRx Corporation (CYTR), hence the stock is down -73.86% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.26% relative to the S&P 500. The 4-week change in the price of the stock is -73.21% and the stock has fallen -6.86% in the past 1 week.

CytRx Corporation (NASDAQ:CYTR): The stock opened at $0.61 on Friday but the bulls could not build on the opening and the stock topped out at $0.62 for the day. The stock traded down to $0.59 during the day, due to lack of any buying support eventually closed down at $0.61 with a loss of -0.49% for the day. The stock had closed at $0.61 on the previous day. The total traded volume was 1,017,235 shares.

The stock has recorded a 20-day Moving Average of 27.54% and the 50-Day Moving Average is 66.51%. CytRx Corporation has dropped 80.41% during the last 3-month period . Year-to-Date the stock performance stands at -77.15%.

CytRx Corporation (CYTR) : Currently there are 3 street experts covering CytRx Corporation (CYTR) stock. The most bullish and bearish price target for the stock is $10 and $1 respectively for the short term. The average price target of all the analysts comes to $4.58. The estimated standard deviation from the target is $4.82.


CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.